Literature DB >> 8898976

Combination effects of poly(ADP-ribose) polymerase inhibitors and DNA-damaging agents in ovarian tumor cell lines--with special reference to cisplatin.

F Bernges1, W J Zeller.   

Abstract

The effects of the poly(ADP-ribose) polymerase inhibitors 4-amino-1,8-naphthalimide (4-ANI), 6(5H)-phenanthridinone (PHD), 1,5-isoquinolinediol (IQD), 3-aminobenzamide (3-AB) or 4-hydroxyquinazoline (4-HYA) on the cytotoxicity of cisplatin were investigated. The human ovarian tumor cell lines SK-OV-3 and OAW 42 and the rat ovarian tumor cell line O-342 as well as its cisplatin (DDP)-resistant subline O-342/DDP were used. Cytotoxicity was determined with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. 1-Methyl-3-nitro-1-nitrosoguanidine (MNNG) plus its respective combinations with poly(ADP-ribose) polymerase inhibitors served as positive controls. In addition, the alkylating agents L-threitol-1,4-bismethanesulfonate (DHB) and 1,3-bis(2-chloroethyl)-1-nitrosourea (carmustine) as well as two other DNA-repair inhibitors caffeine and theophylline were included in the investigations. The cytotoxicity of cisplatin could not be increased by 4-ANI, PHD, IQD, 4-HYA or 3-AB in any cell line investigated, while it was increased by caffeine in lines O-342/DDP and SK-OV-3 as well as by theophylline in lines O-342/DDP, SK-OV-3 and OAW 42. The cytotoxicity of MNNG was increased by combination with 4-ANI, PHD, IQD, 4-HYA, 3-AB or theophylline for all lines except OAW42; in the latter line, only 4-ANI, PHD and IQD increased MNNG cytotoxicity. The cytotoxicity of DHB was increased by 4-ANI, PHD, 4-HYA, theophylline and caffeine in line O-342/DDP; by 4-HYA, theophylline and caffeine in line SK-OV-3; and by theophylline and caffeine in line OAW42. The cytotoxicity of carmustine was increased only by 3-AB in two lines (SK-OV-3 and OAW 42). Results are discussed with regard to different DNA-repair mechanisms.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8898976     DOI: 10.1007/bf01209029

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  53 in total

Review 1.  The molecular biology of apoptosis.

Authors:  D L Vaux; A Strasser
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-19       Impact factor: 11.205

Review 2.  Fundamental studies with cisplatin.

Authors:  B Rosenberg
Journal:  Cancer       Date:  1985-05-15       Impact factor: 6.860

3.  Inhibitors of poly(adenosine diphosphate-ribose) synthesis: effect on other metabolic processes.

Authors:  K M Milam; J E Cleaver
Journal:  Science       Date:  1984-02-10       Impact factor: 47.728

4.  Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease.

Authors:  Z Q Wang; B Auer; L Stingl; H Berghammer; D Haidacher; M Schweiger; E F Wagner
Journal:  Genes Dev       Date:  1995-03-01       Impact factor: 11.361

5.  Increased sensitivity of UV-repair-deficient human cells to DNA bound platinum products which unlike thymine dimers are not recognized by an endonuclease extracted from Micrococcus luteus.

Authors:  H N Fraval; C J Rawlings; J J Roberts
Journal:  Mutat Res       Date:  1978-07       Impact factor: 2.433

6.  Ultraviolet irradiation produces cytotoxic synergy and increased DNA interstrand crosslinking with cis- and trans-diamminedichloroplatinum(II).

Authors:  L J Swinnen; S G Fisher; L C Erickson
Journal:  Carcinogenesis       Date:  1989-08       Impact factor: 4.944

7.  Enhancement of cisplatin (DDP) antitumor activity by 3-aminobenzamide in rat ovarian tumors sensitive and resistant to DDP in vivo.

Authors:  G Chen; W J Zeller
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

8.  Human nucleotide excision repair in vitro: repair of pyrimidine dimers, psoralen and cisplatin adducts by HeLa cell-free extract.

Authors:  I Husain; W Carlton; A Sancar
Journal:  Nucleic Acids Res       Date:  1989-06-26       Impact factor: 16.971

9.  Participation of poly(ADP-ribose) polymerase in the drug sensitivity in human lung cancer cell lines.

Authors:  S Kubo; M Matsutani; K Nakagawa; T Ogura; H Esumi; N Saijo
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

10.  An XPG DNA repair defect causing mutagen hypersensitivity in mouse leukemia L1210 cells.

Authors:  J A Vilpo; L M Vilpo; D E Szymkowski; A O'Donovan; R D Wood
Journal:  Mol Cell Biol       Date:  1995-01       Impact factor: 4.272

View more
  12 in total

1.  Photoaffinity isolation and identification of proteins in cancer cell extracts that bind to platinum-modified DNA.

Authors:  Evan R Guggenheim; Dong Xu; Christiana X Zhang; Pamela V Chang; Stephen J Lippard
Journal:  Chembiochem       Date:  2009-01-05       Impact factor: 3.164

Review 2.  Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy.

Authors:  Yanxin Lu; Yang Liu; Ying Pang; Karel Pacak; Chunzhang Yang
Journal:  Pharmacol Ther       Date:  2018-04-03       Impact factor: 12.310

Review 3.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

4.  Poly(ADP-ribose) polymerase-1 activity facilitates the dissociation of nuclear proteins from platinum-modified DNA.

Authors:  Evan R Guggenheim; Alison E Ondrus; Mohammad Movassaghi; Stephen J Lippard
Journal:  Bioorg Med Chem       Date:  2008-10-14       Impact factor: 3.641

5.  The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice.

Authors:  Majid Ali; Marzieh Kamjoo; Huw D Thomas; Suzanne Kyle; Ivanda Pavlovska; Muhammed Babur; Brian A Telfer; Nicola J Curtin; Kaye J Williams
Journal:  Mol Cancer Ther       Date:  2011-09-16       Impact factor: 6.261

Review 6.  The role of PARP in DNA repair and its therapeutic exploitation.

Authors:  M Javle; N J Curtin
Journal:  Br J Cancer       Date:  2011-10-11       Impact factor: 7.640

7.  Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro.

Authors:  K J Bowman; D R Newell; A H Calvert; N J Curtin
Journal:  Br J Cancer       Date:  2001-01-05       Impact factor: 7.640

Review 8.  An update on PARP inhibitors for the treatment of cancer.

Authors:  Sarah Benafif; Marcia Hall
Journal:  Onco Targets Ther       Date:  2015-02-26       Impact factor: 4.147

9.  Poly(ADP-ribose) polymerase (PARP-1) is not involved in DNA double-strand break recovery.

Authors:  Georges Noël; Nicole Giocanti; Marie Fernet; Frédérique Mégnin-Chanet; Vincent Favaudon
Journal:  BMC Cell Biol       Date:  2003-07-16       Impact factor: 4.241

Review 10.  Poly(adenosine diphosphate-ribose) polymerase as therapeutic target: lessons learned from its inhibitors.

Authors:  Anna Mária Cseh; Zsolt Fábián; Balázs Sümegi; Luca Scorrano
Journal:  Oncotarget       Date:  2017-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.